Iterum Anxiously Awaiting Other Results After SURE 3 Failure

Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.

Illustration of bacteria on colorful background, model of bacteria, microbes, microorganisms,
Sulopenem has shown broad-spectrum activity against most Gram-positive and Gram-negative bacteria

Although Iterum Therapeutics PLC’s sulopenem missed the primary endpoint in the SURE 3 trial in complicated intra-abdominal infections, the four-year-old company believes the Phase III data could still be supportive of a new drug application if the firm’s other Phase III trials are positive.

The company hopes to file an NDA with the US Food and Drug Administration after two other trials, SURE 1...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category